786926 research-article2018 TAK0010.1177/1753944718786926Therapeutic Advances in Cardiovascular DiseaseR Deev, I Plaksa Therapeutic Advances in Cardiovascular Disease Original Research Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication Ther Adv Cardiovasc Dis 2018, Vol 12(9) 237–246 https://doi.org/10.1177/1753944718786926 DOI: 10.1177/ https://doi.org/10.1177/1753944718786926 1753944718786926 © The Author(s), 2018 Reprints and permissions: http://www.sagepub.co.uk/ journalsPermissions.nav Roman Deev, Igor Plaksa , Ilia Bozo, Nina Mzhavanadze, Igor Suchkov, Yuriy Chervyakov, Ilia Staroverov, Roman Kalinin and Artur Isaev Abstract Background: The effective treatment of chronic lower limb ischemia is one of the most challenging issues confronting vascular surgeons Current pharmacological therapies play an auxiliary role and cannot prevent disease progression, and new treatment methods are needed In 2011, a plasmid VEGF65-gene therapy drug was approved in Russia for the treatment of chronic lower limb ischemia (ClinicalTrials.gov identifier: NCT03068585) The objective of this follow-up study was to evaluate the long-term safety and efficacy of gene therapy in patients with limb ischemia of atherosclerotic genesis Aims: To evaluate the long-term safety and efficacy of the therapeutic angiogenesis, 36 patients in the treatment group (pl-VEGF165) and 12 patients in the control group participated in a 5-year follow-up study Planned examinations were carried out annually for years after pl-VEGF165 administration Results: Differences in the frequency of major cardiovascular events (pl-VEGF165 5/36 versus control 2/12; p = 0.85), malignancies (pl-VEGF165 1/36 versus control 0/12; p = 0.38) and impaired vision (there was none in either group) over the 5-year follow-up period did not achieve statistical significance The target limb salvage was 95% (n = 36) and 67% (n = 12) in the pl-VEGF165 and control groups, respectively The pain-free walking distance value increased by 288% from 105.7 ± 16.5 m to 384 ± 39 m in the treatment group by the end of the fifth year, with a peak of 410.6 ± 86.1 m achieved by the end of the third year The anklebrachial index (ABI) increased from 0.47 ± 0.01 to 0.56 ± 0.02 by the end of the first year, with a subsequent slight decrease to 0.51 ± 0.02 by the fifth year The maximum increment of transcutaneous oximetry test (tcoO2) by 36%, from 66.6 ± 3.7 mm Hg to 90.7 ± 4.9 mm Hg, was observed by the end of the second year Conclusion: The therapeutic effect of angiogenesis induction by gene therapy persists for years Keywords: therapeutic angiogenesis, gene therapy, VEGF165, intermittent claudication Received: 17 January 2018; revised manuscript accepted: May 2018 Introduction Despite significant technological advances in the surgical treatment of patients with atherosclerotic lower limb vascular disease, the amputation rate ranges from 188 to 263 per 100,000 population per year in developed countries.1 Based on the data from the Russian Consensus, critical lower limb ischemia (CLI) is a significant cause of amputation in 30,000–40,000 people in the annually.2 Russian Federation At the same time, the results of large pharmacoeconomic studies showed that increased costs for medical care of patients with peripheral arterial disease (PAD) no longer reduce these numbers.3 This is the result of achieving the limit of surgical care capabilities and the moderate ability of most therapeutic agents to correct ischemia This was a prerequisite for conducting clinical trials in the field of Correspondence to: Igor Plaksa Human Stem Cells Institute, Moscow, Russia Moscow City Oncology Hospital No 62, Moscow, Russia i.plaksa2014@yandex.ru Roman Deev Human Stem Cells Institute, Moscow, Russia Ryazan I.P Pavlov State Medical University, Ryazan, Russia Ilia Bozo Human Stem Cells Institute, Moscow, Russia A.I Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia Nina Mzhavanadze Igor Suchkov Roman Kalinin Ryazan I.P Pavlov State Medical University, Ryazan, Russia Yuriy Chervyakov Ilia Staroverov Yaroslavl Regional Clinical Hospital, Yaroslavl, Russia Artur Isaev Human Stem Cells Institute, Moscow, Russia http://tac.sagepub.com 237 Therapeutic Advances in Cardiovascular Disease 12(9) gene therapy.4–5 Numerous publications over the last 20 years have shown that the use of gene therapy constructions with the VEGF gene as an inductor of angiogenesis is well-tolerated and does not have a systemic effect.6 Unfortunately, most of the phase II–III registration studies that aimed to evaluate the potential of therapeutic angiogenesis as a remedy to “save” a limb in patients with terminal disease failed.7 The knowledge accumulated in the field of gene therapy of PAD led to the understanding that its use is most effective at the stage of intermittent claudication, before the development of necrotic ulcerations, since the presence of irreversible tissue changes creates unfavorable conditions for gene-mediated induction of angiogenesis This determined a change in the approach to conducting clinical trials in this field as well as inclusion criteria and efficacy endpoints.8 The paradigm change in the field of PAD gene therapy resulted in the approval of the world’s first gene therapy drug for the treatment of patients in these categories, with the active ingredient plVEGF165 (ClinicalTrials.gov identifier: NCT03068585) The objective of this followup study was to evaluate the long-term safety and efficacy of gene therapy in patients with CLI.9–11 Materials and methods Rationale for the clinical study Preclinical studies of general toxicity (acute, subacute, chronic, and local irritation) and specific toxicity (allergenicity, reproductive and immune toxicity, mutagenicity and carcinogenicity), as well as the detection of specific drug activity, was carried out at the Russian State federal institution the Institute of Toxicology of Federal Medical Biological Agency of Russia, Saint-Petersburg (2008) The tolerability, feasibility, and shortterm efficacy of the study drug were then evaluated in a phase I to IIa multicenter randomized trial that was conducted in 2010 and which enrolled 45 patients The Federal Service on Surveillance of the Ministry Healthcare and Social Development of the Russian Federation granted approval to conduct a phase IIb to III study (approval notice no 177, 21 April 2010) The study protocol was approved by the National Ethics Committee (protocol no 62 from April 2010); local ethics committees have also granted their approval to conduct the study All phases of clinical trials were conducted according to the Declaration of Helsinki of the World Medical Association’s ‘Recommendations guiding physicians in biomedical research involving human subjects’ (1964, 2000), ‘Rules of good clinical practice in the Russian Federation’, OST 42-51199, ICH GCP rules, and valid regulatory requirements The follow-up study protocol was also approved by the local ethics committees of Ryazan State I.P Pavlov Medical University (protocol no from 20 October 2011) and Yaroslavl State Medical Academy (protocol no 30 from November 2011) Study population Having completed the phase IIb/III registration study, 48 of the patients (12 patients in the control group and 36 in the pl-VEGF165 group) gave their consent to participate in a 5-year follow-up study At baseline, all patients were diagnosed with intermittent claudication and/or CLI of atherosclerotic genesis without necrotic changes that correlated with stage II–III under the Fontaine classification as modified by A.V Pokrovsky [a pain-free walking distance (PWD) of not more than 1000 m and no necrotic ulcerations in limb soft tissues] None of the patients with stage III disease could have revascularization surgery because of the lesion extent and the severity of structural changes in the vessel wall Depending upon the anatomy and involvement in a pathological process, the patients had atherosclerotic lesions of the following patterns: proximal – occlusion of the femoral artery and patency of the iliac segment; multilevel – occlusion in the superficial femoral, popliteal and tibial arteries; distal – occlusion or hemodynamically significant stenosis in tibial arteries Description of pl-VEGF165 The study drug is an original gene construction containing a supercoiled plasmid DNA (1.2 mg)encoding pl-VEGF165 as the active substance and is now marketed as “Neovasculgen”.9 plVEGF165 was used only in the phase IIb/III registration clinical study; no re-administration of the drug was done during the subsequent follow up The drug was kept as a lyophilizate dissolved in ml of water for injection immediately before administration The solution was given as 5–10 intramuscular injections into the calf muscles twice, 1.2 mg at an interval of 14 days (a total dose of 2.4 mg) 238 http://tac.sagepub.com R Deev, I Plaksa et al Figure 1. Design and time points of the follow-up study ABI, ankle-brachial index; PWD, pain-free walking distance; TcPO2, Transcutaneous Oximetry Test Design and time points of the follow-up study The phase IIb/III registration clinical study was designed as a randomized, open, comparative study with a 6-month duration A total of 100 patients with CLI were randomized into the control group (n = 25), who received standard conservative therapy without cilostazol and prostaglandins, and the treatment group (n = 75), who received standard conservative treatment and pl-VEGF165 Control examination time points in the follow-up period after the end of the clinical trial were 1, 2, 3, and years after pl-VEGF165 administration (Figure 1) Over this period of time, all patients had standard therapy including 75 mg of acetylsalicylic acid (aspirin)/clopidogrel, statins in individual doses in order to reduce the risk of cardiovascular complications, and pentoxifylline without prostaglandins and prostacyclins Every patient was informed about the study goals and objectives and the potential benefits and risks of participating in it prior to inclusion in the follow-up study All the patients signed the voluntary informed consent form The follow-up study protocol was approved by a local Ethics Committee at every study site (ClinicalTrials.gov identifier: NCT03068585) Safety assessment Adverse events (AEs) and serious adverse events were recorded over years of the follow-up study to evaluate drug safety During screening, the patients had ECG, blood hematology and biochemistry, a coagulation panel and urinalysis performed in order to detect any concomitant and underlying disorders Fluorography, abdominal ultrasound, gastroscopy and colonoscopy were performed if required in order to rule out malignancies and other complications Efficacy assessment The same parameters that were used as efficacy endpoints in the registration clinical study were evaluated during control examinations A PWD value was used as the primary efficacy endpoint It was measured on a treadmill with an elevation angle of 0° and a speed of km/h; the walking distance was registered from the start to pain in the limb muscle (evidence grade B according to the TASC-II) The disease was staged under the Fontaine classification modified by A.V Pokrovsky that is widely applied by Russian and Ukrainian vascular surgeons According to this classification, a PWD of more than 200 m indicates stage IIA disease and of less than 200 m but more than 50 m indicates stage IIB disease The disease is rated as stage III when the PWD is less than 50 m and/or there is resting pain without any ischemic tissue changes (trophic ulcer and/or necrosis) TcPO2 of the involved limb and the ABI were used as secondary efficacy endpoints (Table 1) Mortality and http://tac.sagepub.com 239 Therapeutic Advances in Cardiovascular Disease 12(9) Table 1. Baseline characteristics of 5-year follow-up study patients Parameter Control group (standard therapy) (n = 12) Treatment group (pl-VEGF165) (n = 36) Statistical significance of the differences between groups Average age 64.6 ± 5.2 63.3 ± 9.4 (t test) p = 0.421 M (58.0) 25 (69.4) Chi-square 1.000 F (42.0) 11 (30.6) Yates corrected Chisquare 1.000 Yes (33.4) 10 (27.7) (Chi-square) p = 0.617 No (66.6) 26 (72.3) (Chi-square) p = 0.425 Gender distribution, n (%) Smoking Diabetes mellitus Type I – – Type II (8.3) (11.1) (Chi-square) p = 0.674 IIa (0.0) (5.6) (Chi-square) p = 0.326 IIb (75.0) 21 (58.3) (Chi-square) p = 0.423 III (25.0) 13 (36.1) (Chi-square) p = 0.143 Proximal (16.0) 10 (27.8) (Chi-square) p = 0.246 Distal (50.0) 15 (41.6) (Chi-square) p = 0.465 Multilevel disease (34.0) 11 (30.6) (Chi-square) p = 0.674 PWD, m 105.7 ± 16.5 99.3 ± 8.1 (Mann–Whitney U test) 0.672 ABI, U 0.47 ± 0.01 0.39 ± 0.03 (Mann–Whitney U test) 0.062 TcPO2, mmHg 66.7 ± 3.8 64.2 ± 3.9 (Mann–Whitney U test) 0.681 Severity of CLI, n % Level of occlusion, n (%) ABI, ankle-brachial index; CLI, chronic limb ischemia; PWD, pain-Free walking distance; TcPO2, transcutaneous oxygen pressure amputation rates by the end of the 5-year followup study were also calculated in both groups Statistical data processing A sample size of 28 patients in each group in the phase IIb/III registration study was estimated to detect a 0.75 standardized difference (80% power, p = 0.05), assuming the target difference and standard deviation for PWD to be 75 m and 100 m, respectively We decided to use a 3:1 test/ control group ratio in order to make the test group sample more representative.9 The power analysis for the subsequent follow up was not made 240 http://tac.sagepub.com R Deev, I Plaksa et al Table 2. Mortality and serious adverse events in the treatment and control study groups during the 5-year follow-up study Parameter Control (n = 12) pl-VEGF165 (n = 36) Statistical significance of the differences between groups (Chi-square) Number of amputations (33%) (5%) p = 0.008* AMI (8.3%) (8.3%) p = 1.000 ACVE (8.3%) (5.5%) p = 0.864 Cancer (2.7%) p = 0.942 Mortality (16%) (16.6%) p = 0.845 ACVE, acute cerebrovascular event; AMI, acute myocardial infarction * p < 0.01 because patients after the registration trial were included freely on the basis of their own desire to participate, depending on their capabilities Absolute values of the efficacy endpoints (PWD, ABI, and TcPO2) complied with a non-normal distribution Therefore, nonparametric methods (a Mann–Whitney U test and a Wilcoxon signedrank test) were used for the statistical analysis; additionally, a Chi-squared test was used to evaluate the significance of differences in the event frequencies in pl-VEGF165 and control groups Results Baseline characteristics of patients in the follow-up study A comparative analysis of the baseline characteristics showed that the groups were comparable for gender composition, age and primary and secondary efficacy endpoint values Baseline PWD values were comparable between both groups at 105.7 ± 16.5 m and 99.3 ± 8.4 m (p = 0.672) in the pl-VEGF165 and control groups, respectively There were no significant differences in the structure of patient distribution for disease stages and level of lower limb vascular lesions; patients with stage IIB disease and distal lesions prevailed in both groups (Table 1) Five patients from the treatment group and one from the control group had resting pains of various intensities at the beginning of the study Safety assessment No AEs related to the use of pl-VEGF165 were recorded Neither tumor formation, nor impaired vision nor any other pathology that could indirectly indicate angiogenic therapy complications were detected at any time points during the follow-up study The mortality rate over the entire follow-up period was 16.6%, 6/36 and 2/12 in the pl-VEGF165 and control groups, respectively Two patients from the pl-VEGF165 group (n = 36) and four patients from the control group (n = 12) underwent amputations of the lower limb as a result of ischemia progression and revascularization surgery infeasibility Thus, the amputationfree survival was 95% and 67%, respectively (Table 2) Two patients from the control group and five patients from the pl-VEGF165 group had cardiovascular complications as a result of a generalized atherosclerotic lesion of the vessel wall In the third year of the follow-up study, metastatic renal cancer was diagnosed in one patient from the treatment group, which was fatal Efficacy assessment The maximum increase of PWD by 288% from 105.7 ± 16.5 m to 410.6 ± 86.1 m (p = 0.000) was observed in the treatment group by the end of the third follow-up year In general, these values stabilized in the subsequent years; there was only a slight decrease by 26.5 m to 384.1 ± 39.6 m by the end of the fifth follow-up year The PWD values were almost unchanged in the control group (Table 3) The most evident increase of PWD in the plVEGF165 group was observed in patients with stage III disease (n = 13) The value increased from 24.3 ± 5.3 m to 378 ± 73.1 m by the end of the 5-year follow-up period (p = 0.0001) At http://tac.sagepub.com 241 0.39 ± 0.03 ABI 66.7 ± 3.8 TcPO2 99.3 ± 8.1 0.47 ± 0.01 ABI PWD 105.7 ± 16.6 PWD Treatment group (n = 36) Control group (n = 12) Baseline 36/12 p* = 0.002 p* = 0.001 p* = 0.024 p = 0.028 p* = 0.016 p = 0.152 p* = 0.000 p = 0.006 p* = 0.013 p = 0.210 p* = 0.172 p = 0.860 p* = 0.762 p = 1.000 p = 0.846 p* = 0.024 0.52 ± 0.03 p = 0.012 p* = 0.032 0.39 ± 0.03 p = 1.000 0.49 ± 0.02 p = 0.762 109.4 ± 9.8 97.6 ± 9.2 123.1 ± 8.4 p = 0.032 86.9 ± 2.3 62.7 ± 4.9 90.7 ± 4.9 p = 0.681 0.56 ± 0.02 0.5 ± 0.03 0.55 ± 0.02 p = 0.240 p = 0.012 p = 0.008 354.7 ± 54.4 Year 30/10 305.5 ± 45.1 Year 36/12 223.4 ± 30.8 months 36/12 Statistical significance of in-group differences, M ± m Parameter Table 3. Primary and secondary efficacy endpoints in the 5-year follow-up study p* = 0.014 p = 1.000 0.48 ± 0.02 p* = 0.243 p = 0.340 110.0 ± 10.1 p* = 0.014 p = 0.125 88.4 ± 1.1 p* = 0.046 p = 0.265 0.52 ± 0.03 p* = 0.000 p = 0.160 410.7 ± 86.1 Year 28/8 p* = 0.264 p = 0.640 0.42 ± 0.02 p* = 1.000 p = 0.124 98.3 ± 5.4 p* = 0.017 p = 0.426 86.9 ± 1.1 p* = 0.050 p = 0.324 0.51 ± 0.02 p* = 0.001 p = 0.021 365.8 ± 39.3 Year 26/5 p* = 0.320 p = 1.000 0.42 ± 0.02 p* = 0.842 p = 0.072 86.7 ± 4.6 p* = 0.021 p = 0.214 84.1 ± 1.8 p* = 0.049 p = 1.000 0.51 ± 0.02 p* = 0.003 p = 0.108 384.1 ± 39.6 Year 22/3 Therapeutic Advances in Cardiovascular Disease 12(9) 242 http://tac.sagepub.com p = 0.672 p = 0.120 p = 0.681 ABI (36/12) TcPO2 (36/12) 64.2 ± 3.9 Baseline 36/12 p = 0.680 p = 0.010 p = 0.012 p = 0.353 p = 0.000 p = 0.009 p = 0.239 p = 0.000 p* = 0.010 p* = 0.014 p = 0.001 p = 0.052 p = 0.025 p = 0.312 81.7 ± 2.0 Year 30/10 76.2 ± 2.0 Year 36/12 60.6 ± 4.6 months 36/12 Statistical significance of in-group differences, M ± m PWD (36/12) TcPO2 Parameter p = 0.016 p = 0.285 p = 0.000 p* = 0.023 p = 0.210 76.8 ± 2.2 Year 28/8 p = 0.052 p = 0.024 p = 0.000 p* = 0.032 p = 0.462 77.3 ± 1.1 Year 26/5 ABI, ankle-brachial index; CLI, chronic limb ischemia; PWD, pain-free walking distance; TcPO2, transcutaneous oxygen pressure; p*, compared with baseline Significance of differences between groups, p value Table (Continued) p = 0.026 p = 0.010 p = 0.000 p* = 0.042 p = 0.121 73.6 ± 1.2 Year 22/3 R Deev, I Plaksa et al http://tac.sagepub.com 243 Therapeutic Advances in Cardiovascular Disease 12(9) the same time, unlike the dynamics of mean values in the treatment group in general, the maximum incremental value was observed only by the end of the fifth follow-up year Depending upon the level of lesion, patients with distal and multilevel disease had the highest incremental value, from 89 ± 20.9 to 510 ± 90.7 (p = 0.0001) and from 109.1 ± 43.5 to 364.4 ± 49.8 (p = 0.001), respectively Positive changes in the PWD, that is from 127.8 ± 19.7 to 218.0 ± 57.4 (p = 0.012), were less evident for proximal lesions No selective analysis in dependence upon a disease stage and a level of occlusion was performed in the control group because of the small sample size (Table 3) The mean ABI value increased from 0.47 ± 0.01 to 0.51 ± 0.02 (p = 0.049) in the treatment group over the 5-year follow-up period, with a peak of 0.56 ± 0.02 achieved by the end of the first year of follow-up (p = 0.028) Macrohemodynamic parameters correlated with TcPO2 values that increased by 27% from 66.7 ± 3.8 mmHg to 84.1 ± 1.8 mmHg (p = 0.021), with a peak at 90.6 ± 0.4 mmHg in the second year of follow up In the control group, the ABI slightly increased from 0.39 ± 0.03 to 0.42 ± 0.02 (p = 0.320), with subtle fluctuations over the entire 5-year follow-up period TcPO2 increased by 26% from 64.2 ± 3.4 to 81 ± 2.0 mmHg by the end of the second year of follow up, and then there was a moderate gradual decrease by 7.4% by the end of the fifth year (Table 3) Discussion The objective of the 5-year follow-up study was to evaluate the long-term tolerability and efficacy of angiogenesis induction with gene therapy in patients with CLI The results demonstrated that the use of pl-VEGF165 was not followed by the increased frequency of cardiovascular complications, malignancies or impaired vision This gives evidence that the drug is a local angiogenesis inductor without a systemic effect To date, this is one of the most prolonged studies aiming to evaluate the long-term safety and efficacy of gene therapy Studies performed by other teams also demonstrate that the safety profile of gene therapy with VEGF is acceptable An 8-year follow-up study involving patients with coronary artery disease after administration of VEGF-Adv (n = 37) and pl-VEGF (n = 28) demonstrated that the use of gene therapy to induce angiogenesis did not result in increased frequency of tumor formation or cardiovascular complications compared with a placebo (n = 38).12 An intracoronary infusion of VEGF-Adv caused only transitory increased lactate dehydrogenase (LDHG) levels in several recipients The results of the 10-year follow-up study of patients with CLI who had intramuscular administration of VEGF-Adv (n = 18) and pl-VEGF (n = 17) within the placebocontrolled phase II study also demonstrated the tolerability of this treatment approach.13 None of the follow-up studies revealed increased systemic VEGF levels or increased frequency of diabetic retinopathy after gene therapeutic constructions were administered that could indirectly indicate a systemic effect Thus, to date there is no evidence that VEGF-based gene therapy is capable of inducing the growth of blood vessels at a considerable distance from an injection site This is consistent with our concept of pl-VEGF165 as a local inductor of angiogenesis The registered clinical study aimed to evaluate the possible use of gene therapy to prevent ischemia progression to necrotic ulcerations Therefore, target limb salvage was not used as the efficacy endpoint because patients in these categories not have an immediate threat of losing their limbs in the near future.9,10 However, the 5-year follow-up study demonstrated that the long-term amputation rate in the pl-VEGF165 group was significantly lower (p = 0.008) The results that were obtained cannot be extrapolated to the whole population of patients with CLI because of the small sample size However, they confirm our working hypothesis that the use of gene therapy before irreversible structural changes develop in tissues can reduce the risk of ischemia progression and thereby decrease the likelihood of amputation in the future To date, numerous data have been obtained in the field of gene therapy in cardiovascular diseases that indicate that use of gene therapy constructions with the gene VEGF is an effective tool to correct lower limb ischemia However, the attitude of the vascular community is generally skeptical This is largely because since work began in this field, gene therapy has been considered primarily as a tool to “save” a limb in patients with CLI over a long period of time This is the basis of most studies, with participation of patients with a terminal form (stage) of the disease and the use of strict efficacy endpoints This approach is 244 http://tac.sagepub.com R Deev, I Plaksa et al caused by ethical aspects because of traditional alertness about the safety of VEGF gene-based constructions, and by the availability of a large arsenal of surgical techniques with definite efficacy that in general determined the enrollment of patients who are poor surgical candidates The results of our studies show that early forms of CLI before the development of apparent and irreversible trophic changes, such as necrosis and ulcers, are a therapeutic window for the use of plVEGF165 The induction of angiogenesis in this period can significantly improve the functional state of patients with PAD and prevent the progression of ischemia The main limitation of this study was its openlabel nature, suggesting a high risk of detection bias for subjective outcomes like PWD Also, the power analysis was initially made only for the phase IIb/III registration study because subsequent participation of patients in the follow-up study was based on their own desire, depending on their capabilities Although the open-label use of study drugs is a limitation, this study was randomized and involved three centers, and patient enrollment decisions were made independently by a team of vascular surgeons and radiologists on the basis of angiographic results, disease history, previous procedures and concomitant pathology Additionally, the prolonged stable therapeutic effect of the gene therapy during the 5-year follow-up period is evidence that it is not connected with a placebo effect Conclusion The use of pl-VEGF165 demonstrates good tolerability and is not followed by tumor formation, cardiovascular complications or impaired vision When pl-VEGF165 is used before necrotic-ulcerative changes develop in patients with CLI, its therapeutic effect persists for at least years Acknowledgements The authors would like to thank the clinical investigators for their contribution in conducting this trial and participating in the studies Ethics statement The study was conducted according to the Declaration of Helsinki of the World Medical Association ‘Recommendations guiding physicians in biomedical research involving human subjects’ (1964, 2000), ‘Rules of good clinical practice in the Russian Federation’, OST 42-511-99, ICH GCP rules and valid regulatory requirements Funding This study was funded by the PJSC Human Stem Cells Institute (Moscow, Russia) Conflict of interest statement The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A.A Isaev, I Ya Bozo, R.V Deev and I.L Plaksa are employees of the PJSC Human Stem Cells Institute A.A Isaev is a shareholder of the PJSC Human Stem Cells Institute ORCID iD Igor Plaksa https://orcid.org/0000-0001-6600-0933 References Goodney PP, Beck AW, Nagle J, et al National trends in lower extremity bypass surgery, endovascular interventions, and major amputations J Vasc Surg 2009; 50: 54–60 Bokeriia LA, Pokrovskiĭ AV, Belov UV, et al National guidelines for management of patients with pathology of lower limb arteries Angiology Vasc Surg 2013; 19: 1–67 Goodney PP, Travis LL, Brooke BS, et al Relationship between regional spending on vascular care and amputation rate JAMA Surg 2014; 149: 34–42 Morishita R, Nakamura S, Hayashi S, et al Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy Hypertension 1999; 33: 1379–1384 Nikol S, Baumgartner I, Van Belle E, et al Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia Mol Ther 2008; 16: 972– 978 Gupta R, Tongers J and Losordo DW Human studies of angiogenic gene therapy Circ Res 2009; 105: 724–736 Cooke JP and Losordo DW Modulating the vascular response to limb ischemia: angiogenic and cell therapies Circ Res 2015; 116: 1561–1578 Ylä-Herttuala S, Bridges C, Katz MG, et al Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur Heart J 2017; 38: 1365–1371 http://tac.sagepub.com 245 Therapeutic Advances in Cardiovascular Disease 12(9) Deev R, Bozo I, Mzhavanadze N, et al pCMVVEGF165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia J Cardiovasc Pharmacol Ther 2015; 20: 473–482 Visit SAGE journals online http://tac.sagepub.com SAGE journals 10 Deev R, Plaksa I, Bozo I, et al Results of an international postmarketing surveillance study of pl-VEGF165 safety and efficacy in 210 patients with peripheral arterial disease Am J Cardiovasc Drugs Epub ahead of print 2017 DOI: 10.1007/ s40256-016-0210-3 11 Yudin M, Plaksa I, Mzhavanadze N, et al Estimation of systemic distribution and angiogenic effect of pl-VEGF165 in the model of limb ischemia Circulation Pathology and Cardiac Surgery 2015; 19: 33–42 12 Hedman M, Muona K, Hedman A, et al Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer Gene Ther 2009; 16: 629–634 13 Muona K, Mäkinen K, Hedman M, et al 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb Gene Ther 2012; 19: 392–395 246 http://tac.sagepub.com